Clinical Trial Update: Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intratumoral toluenesulfonamide (PTS) for stage IV driver gene-negative non-small cell lung cancer, with or without chemoimmunotherapy,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Toluenesulfonamide intratumoral injection (PTS) (toluenesulfonamide)

Snippet

Sponsor: Zhou Chengzhi | Conditions: Lung Cancer | Phase 3 | Status: RECRUITING